WO2018030683A1 - Composition pharmaceutique comprenant comme principe actif la protéine thymidine phosphorylase (tymp), destinée à la prévention ou au traitement de la chute des cheveux - Google Patents

Composition pharmaceutique comprenant comme principe actif la protéine thymidine phosphorylase (tymp), destinée à la prévention ou au traitement de la chute des cheveux Download PDF

Info

Publication number
WO2018030683A1
WO2018030683A1 PCT/KR2017/008117 KR2017008117W WO2018030683A1 WO 2018030683 A1 WO2018030683 A1 WO 2018030683A1 KR 2017008117 W KR2017008117 W KR 2017008117W WO 2018030683 A1 WO2018030683 A1 WO 2018030683A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair
hair loss
protein
tymp
composition
Prior art date
Application number
PCT/KR2017/008117
Other languages
English (en)
Korean (ko)
Inventor
송순욱
성종혁
Original Assignee
에스씨엠생명과학 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스씨엠생명과학 주식회사 filed Critical 에스씨엠생명과학 주식회사
Publication of WO2018030683A1 publication Critical patent/WO2018030683A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat

Definitions

  • the present invention is a pharmaceutical composition for preventing or treating hair loss, a composition for preventing or improving hair loss, a composition for preventing or improving hair loss, a composition for promoting hair growth or promoting hair loss, a method for preventing or treating hair loss, a method for improving hair loss, and a hair growth comprising a thymidine phosphorylase (TYMP) protein as an active ingredient It is about hair growth promotion method.
  • TYMP thymidine phosphorylase
  • Hair loss refers to a condition in which hair is not normally present in the area where hair is normally present, and generally means that the hair of the scalp (coarse black hair) falls out. Unlike virgin hair, which has no color and thick color, it can cause cosmetic problems if it falls out. Koreans with lower hair density than Westerners have 5-70,000 hairs, and about 50-70 hairs per day are normal. Therefore, hair loss may be in progress if the number of hairs that fall after sleeping or when you wash your hair exceeds 100.
  • Alopecia areata is thought to be an autoimmune disease. Resting alopecia is a temporary hair loss that occurs after severe physical and mental stress such as endocrine disease, nutritional deficiency, drug use, childbirth, fever, and surgery.
  • male-type hair loss is gradually thinning hair from the 20s or 30s in people with a family history of baldness, hair loss proceeds.
  • the forehead and head line is pushed backward, the forehead widens in the M-shape with both temporal heads and hair loss progresses gradually in the crown of the head.
  • Female hair loss is characterized in that the hairline on the forehead is thinned and hair thinner compared to male hair loss.
  • female hair loss is so weak that hair loss is rare and complete baldness, as in male hair loss.
  • Alopecia areata is also characterized by the development of round or oval bald spots of varying sizes (hair loss that looks like dots).
  • alopecia areata frontal alopecia
  • hair thinning is reduced overall. As the causative stimulus is removed, hair loss is reduced as restorative hair returns to normal for several months.
  • a male or female hair loss drug such as minoxidil, a drug such as finasteride, a hair transplant, and the like are used.
  • alopecia topical steroid preparations, systemic steroid preparations, immunotherapy and the like are used. Resting alopecia causes hair to recover when the cause is removed, so it is important to identify and treat the cause.
  • alopecia causes hair to recover when the cause is removed, so it is important to identify and treat the cause.
  • there is a problem of side effects because it depends on drug therapy, steroid preparations, etc.
  • the treatment cost also increases significantly if the treatment using drugs or hair transplantation.
  • Minoxidil and finasteride are representative drugs used to promote hair growth.
  • Minoxidil from the US Upzone may cause side effects such as swelling, arrhythmia and unwanted hairs on long term application.
  • the effect of minoxidil is most effective between 6 months and 1 year from use and then gradually It is known that the effect is reduced.
  • Finasteride developed by Merck, is known to inhibit the activity of 5- ⁇ -reductase, an enzyme that acts on male hormone testosterone metabolism in hair follicles. An increase in suicidal thoughts has been reported.
  • it is not applicable to women of childbearing age or pregnant women because it increases the probability of birth of birth defects.
  • hair loss progresses again if both drugs are discontinued.
  • Valproic acid but taking it during pregnancy is known to greatly reduce the child's cognitive development ability.
  • various types of conventional hair regrowth have been attempted to help hair growth for the purpose of promoting blood circulation of the scalp and nourishing hair roots.
  • the present invention is also toxic and side effects are severe and the effect is insufficient. .
  • the present inventors have made intensive efforts to develop a material capable of preventing hair loss and promoting hair growth without side effects, and confirmed that the TYMP (thymidine phosphorylase) protein present in the body has an effect of promoting hair growth. Completed.
  • TYMP thymidine phosphorylase
  • Another object of the present invention is to provide a quasi-drug composition, cosmetic composition and food composition for preventing or improving hair loss containing TYMP protein as an active ingredient.
  • Another object of the present invention to provide a pharmaceutical composition, quasi-drug composition, cosmetic composition and food composition for promoting hair growth or hair growth comprising TYMP protein as an active ingredient.
  • Still another object of the present invention is to provide a method for preventing or treating hair loss, a method for improving hair loss, and a method for promoting hair growth or hair growth, comprising: treating a subject with TYMP protein.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of hair loss comprising TYMP (thymidine phosphorylase) protein as an active ingredient.
  • TYMP thymidine phosphorylase
  • the present invention provides a quasi-drug composition for preventing or improving hair loss comprising TYMP protein as an active ingredient.
  • the present invention also provides a cosmetic composition for preventing or improving hair loss comprising TYMP protein as an active ingredient.
  • the present invention provides a food composition for preventing or improving hair loss comprising TYMP protein as an active ingredient.
  • the present invention provides a pharmaceutical composition for promoting hair growth or hair growth comprising TYMP protein as an active ingredient.
  • the present invention provides a quasi-drug composition for promoting hair growth or hair growth comprising TYMP protein as an active ingredient.
  • the present invention also provides a cosmetic composition for promoting hair growth or hair growth comprising TYMP protein as an active ingredient.
  • the present invention provides a food composition for promoting hair growth or hair growth comprising TYMP protein as an active ingredient.
  • the present invention also provides a method for preventing or treating hair loss, comprising the step of treating the subject with TYMP protein.
  • the present invention provides a method for improving hair loss comprising the step of treating the subject with a TYMP protein.
  • the present invention provides a method for promoting hair growth or hair growth comprising a; treating the subject with a TYMP protein.
  • composition for preventing hair loss or promoting hair growth comprising TYMP (thymidine phosphorylase) protein according to the present invention as an active ingredient has no side effects when treating hair loss, and can be used as a medicine due to its excellent hair growth effect even in a short time. It can be usefully used for health functional food.
  • TYMP thymidine phosphorylase
  • Figure 1 is a diagram showing the results of measuring the cell proliferation for 40 hours after treatment with TYMP protein DPC.
  • Figure 2 is a diagram showing the dorsal portion of the mouse after 15 days after subcutaneous injection of TYMP protein after removing hair using a hair removal agent in the back of C3H / HeN mice.
  • Figure 3 is a diagram showing the result of measuring the increased hair growth weight (mg) of the mouse after 15 days after subcutaneous injection of TYMP protein after hair removal using a hair removal agent in the back of C3H / HeN mice.
  • the present invention provides a pharmaceutical composition for preventing or treating hair loss and promoting hair growth or hair growth comprising TYMP protein as an active ingredient.
  • TYMP thymidine phosphorylase
  • TYMP is an enzyme that reversibly converts thymidine into thymine and 2-deoxyribose-1-phosphate and is known to be involved in DNA synthesis.
  • high expression of TYMP was observed in various solid tumors, centering on gastric cancer and colorectal cancer, and positive expression correlated with angiogenesis, invasion, metastasis, and expression of TYMP was one of the prognostic factors. was found to be.
  • high expression at the site of the disease has been reported, mainly in inflammatory diseases, in patients with glomerulonephritis, interstitial cystitis, chronic arthritis rheumatism, and inflammatory bowel disease.
  • TYMP is associated with hair loss symptoms and hair growth effects.
  • the TYMP protein may consist of all or part of a peptide having a prophylactic effect of preventing or treating hair loss, hair growth or hair growth, and may preferably be composed of the amino acid sequence of SEQ ID NO: 1, and functional equivalents and variants of the protein. It includes.
  • proteins and polypeptides that do not alter the activity of the protein molecule as a whole and proteins that can function functionally are included in the scope of the present invention.
  • the variant may be, for example, one or several amino acids deleted, substituted or added to the amino acid sequence, having 95% or more, preferably 98% or more, and more preferably 99% or more identity with the amino acid sequence.
  • identity means that the other amino acid sequence includes the gap between two amino acid sequences or the other amino acid sequences, including the number of gaps, when the gap is introduced to the highest amino acid sequence. The ratio (%) of the number of the same amino acid residue of the amino acid sequence of is referred to.
  • a few means the integer of 2-10, for example, the integer of 2-7, 2-5, 2-4, 2-3.
  • the variant based on polymorphisms such as SNP (monobasic polymorphism), a splice variant, etc. are mentioned.
  • the substitution is a conservative amino acid substitution. It is because conservative amino acid substitutions can have a structure or property substantially equivalent to human TYMP which has the said amino acid sequence.
  • amino acids are non-polar amino acids (glycine, alanine, phenylalanine, valine, leucine, isoleucine, methionine, proline, tryptophan) and polar amino acids (amino acids other than nonpolar amino acids), charged amino acids (acidic amino acids (aspartic acid, glutamic acid) and basic) Amino acids (arginine, histidine, lysine)) and uncharged amino acids (amino acids other than charged amino acids), aromatic amino acids (phenylalanine, tryptophan, tyrosine), branched amino acids (leucine, isoleucine, valine) and aliphatic amino acids (glycine, alanine, leucine) , Isoleucine, valine), and the like are known.
  • the protein may include a protein having increased structural stability or increased protein activity against heat, pH, etc. of the protein by variation or modification on the amino acid sequence.
  • the gene encoding the TYMP protein may be composed of the nucleotide sequence of SEQ ID NO: 2, variants which can function functionally the same as the nucleotides are included in the scope of the present invention.
  • the variant capable of the functionally identical function is at least 70%, preferably 80% or more, more preferably 90% or more of the nucleotide sequence represented by SEQ ID NO: 2 as a result of the addition, substitution or deletion of base. And, more preferably, having a sequence homology of 95% or more, it means a base sequence capable of encoding a protein that exhibits substantially homogeneous physiological activity with a protein encoded by the nucleotide sequence represented by SEQ ID NO: 2. For example, although some sequences have been modified by deletion, substitution or insertion, they include variants that can function functionally identical to nucleic acid molecules encoding the TYMP protein. It is a concept.
  • the term 'hair loss' may fall under the normal hair growth level if the number of hairs is less than the general number without any particular limitation, and preferably consists of male hair loss, female hair loss, circular hair loss and resting hair loss. Any one or more selected from the group may correspond to hair loss being treated or prevented by the composition according to the present invention.
  • the composition according to the present invention is also excellent in preventing hair loss before hair loss begins.
  • the term 'hair growth' refers to hairy, and 'hair growth' refers to hair growth.
  • the effect of the composition according to the invention also includes the effect of promoting hair growth or hair growth.
  • prevention means any action that inhibits or delays hair loss by administration of a composition of the present invention
  • treatment means that the symptoms caused by hair loss are improved or beneficially altered by the composition of the present invention. It means all actions.
  • compositions of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
  • pharmaceutical compositions according to the invention are each formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories, and sterile injectable solutions according to a conventional method. Can be used. Suitable formulations known in the art are preferably those described in the literature.
  • Carriers, excipients and diluents that may be included in the pharmaceutical compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • the pharmaceutical composition When formulating the pharmaceutical composition according to the present invention, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. which are commonly used.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin, and the like in the active ingredient. Mix is prepared.
  • lubricants such as magnesium stearate and talc are also used.
  • Liquid preparations for oral administration include suspensions, solution solutions, emulsions, and syrups, and various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, etc. may be used.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • composition of the present invention may be administered in a pharmaceutically effective amount.
  • the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level is determined by the type and severity, age, sex, disease of the individual. It can be determined according to the type, activity of the drug, sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including the drug used concurrently, and other factors well known in the medical field.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations.
  • the preferred dosage of the composition of the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration of time, and the suitable total daily dosage can be determined by the practitioner within the correct medical judgment. Generally, an amount of 0.001 to 1000 mg / kg, preferably 0.05 to 200 mg / kg, more preferably 0.1 to 100 mg / kg, may be administered once to several times daily.
  • the object is not particularly limited as long as it is an object for the purpose of preventing or treating hair loss, and any object can be applied.
  • transdermal administration through topical application may be used, but is not limited thereto.
  • the method of administering the pharmaceutical composition according to the present invention is not particularly limited, and may be administered orally, or applied to the hair loss site or applied to the site where the progress of hair loss is foreseen.
  • the method of administration there is no particular limitation on the method of administration, and it is also possible to inject directly in the form of injection to the site where hair loss or progression of hair loss is foreseen.
  • the method of administration is not particularly limited, so it is possible to inject by injection into an artery or vein.
  • the dosage level selected from the composition will also depend on the activity of the active ingredient, the route of administration, the severity of the hair loss being treated and the condition and previous history of hair loss being treated. However, it is within the knowledge of the art to start with a lower dose of active ingredient than is required to achieve the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved. It can be determined according to gender, body type and weight.
  • the composition may be further processed before being formulated into a pharmaceutically acceptable pharmaceutical formulation, and may preferably be ground or ground into smaller particles. The composition will also vary depending on the condition and the patient being treated, but this can be determined non-originally.
  • compositions of the present invention have formulations that can be administered by methods such as direct application or spreading on the skin, such as hair or scalp, such as creams, lotions, ointments, aerosols, shampoos, gels, or packs. It may be.
  • Methods for the formulation or formulation suitable for each formulation are well known in the art. Those skilled in the art can appropriately select and use various combinations of ingredients used to prepare conventional external preparations in preparing these formulations.
  • Hair to which the composition of the present invention is applied includes hair follicles and hair follicles of the head, hair and eyelashes, and eyelashes, beards, armpits, pubic hair, and all parts of the hair root and hair follicles throughout the body.
  • the present invention also provides a quasi-drug composition for preventing or improving hair loss and promoting hair growth or hair growth comprising TYMP protein as an active ingredient.
  • the term "quasi drug” refers to a fiber, rubber product or the like used for the purpose of treating, alleviating, treating or preventing a disease of a human or animal, has a weak action on the human body or does not directly act on the human body, Or non-machinery and the like, or any of the agents used for sterilization, insecticide, and similar purposes for the prevention of infection, for the purpose of diagnosing, treating, reducing, treating or preventing human or animal diseases.
  • articles to be used which are not instruments, machines or devices, and articles which are used for the purpose of pharmacologically affecting the structure and function of humans or animals, except those which are not instruments, machines or devices. Also includes supplies.
  • the composition of the present invention When the composition of the present invention is included in a quasi-drug for the purpose of preventing or improving hair loss, promoting hair growth or hair growth, the composition may be used as it is or may be used together with other quasi-drug components, and may be appropriately used according to a conventional method. have.
  • the mixing amount of the active ingredient can be appropriately determined depending on the intended use.
  • the quasi-drug of the present invention is not particularly limited thereto, but may be prepared and used, for example, in the form of a cream, lotion, aerosol, shampoo, gel or pack.
  • creams, ointments, shampoos, gels or packs white petrolatum, yellow petrolatum, lanolin, bleached beeswax, cetanol, stearyl alcohol, stearic acid, hardened oil, gelled hydrocarbons, polyethylene glycol, liquid paraffin, squalane, etc.
  • Solvents and dissolving aids such as oleic acid, isopropyl myristate, glycerin triisooctanoate, crotamiton, diethyl sebacate, diisopropyl adipropyl, hexyl laurate, fatty acids, fatty acid esters, aliphatic alcohols and vegetable oils;
  • Antioxidants such as tocopherol derivatives, L-ascorbic acid, dibutylhydroxytoluene and butylhydroxyanisole; Preservatives such as parahydroxybenzoic acid ester;
  • Moisturizing agents such as glycerin, propylene glycol and sodium hyaluronate;
  • Surfactants such as polyoxyethylene derivative, glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester and lecithin;
  • Thickeners such as carboxyvinyl
  • a stabilizer, a preservative, an absorption promoter, a pH adjuster, and other suitable additives can be mix
  • the present invention provides a cosmetic composition for preventing or improving hair loss and promoting hair growth or hair growth comprising TYMP protein as an active ingredient.
  • the cosmetic composition is a skin external preparation formulation of hair tonic, hair cream, hair lotion, hair shampoo, hair rinse, hair conditioner, hair spray, hair aerosol, pomade, powder gel, hair pack, hair treatment, eyebrow regrowth, eyelash regrowth, eyelash It may be a formulation of a nutrient, but is not limited thereto.
  • composition for preventing or improving hair loss, hair growth or hair growth promoting composition of the present invention can be used for pets different from the formulation.
  • it can be prepared in various forms such as solution, sol-gel, emulsion, oil, wax, aerosol, etc. such as pet shampoo and pet rinse. It can be prepared by addition.
  • the cosmetic composition of the present invention may include without limitation the conventionally acceptable ingredients in addition to the active ingredient, and includes conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, and carriers. can do.
  • conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, and carriers. can do.
  • any one or more of a synthetic surfactant, a preservative, a thickening agent, a viscosity adjusting agent, a pH adjusting agent, a perfume, a dye, a hair conditioner, and water, which are cleaning components, may be contained.
  • synthetic anionic surfactants include alkyl and alkyl ether sulfates, and representative examples thereof include sodium lauryl sulfate, lauryl ammonium sulfate, lauryl sulfate triethanolamine, polyoxyethylene lauryl sulfate, and polyoxyethylene lauryl ammonium sulfate. have.
  • synthetic amphoteric surfactants are alkyl betamin and alkyl amidopropyl betaine, and representative examples thereof are cocodimethyl carboxymethyl betaine, lauryldimethyl carboxymethyl betaine, lauryl dimethyl alpha-carboxyethyl betaine. , Cetyl dimethyl carboxymethyl betaine, cocamidopropyl betaine and the like.
  • the nonionic surfactants include alkanol amides and amine oxides, such as lauryl diethyl amine oxide, palm oil alkyldimethyl amine oxide, lauric acid diethanol amide, palm oil fatty acid diethanolamide, palm oil fatty acid monoethanolamide, and the like.
  • optional ingredients used in the present invention are well known to those skilled in the art as conventional optional ingredients for maintaining basic physical properties and quality as shampoos.
  • Such optional ingredients include pearlescent aids, preservatives, thickeners and viscosity adjusting agents, pH adjusting agents, perfumes, dyes, hair conditioning agents.
  • Pearlescent aids such as, for example, ethylene glycol monostearate, ethylene glycol distearate; Preservatives such as methyl paraoxycyanate, methylchloro isothiazolinone and a mixture of methyl isothiazolinone; Thickeners and viscosity modifiers such as sodium chloride, ammonium chloride, propylene glycol; PH adjusters such as citric acid, phosphoric acid, sodium hydroxide, potassium hydroxide; Dyestuffs such as polyquaternium-10, polyquaternium-7, methylpolysiloxanes, dimethiconecopolyols, hair conditioning agents such as hydrolyzed animal proteins, water soluble tars are used, and fragrance may also be used.
  • Preservatives such as methyl paraoxycyanate, methylchloro isothiazolinone and a mixture of methyl isothiazolinone
  • Thickeners and viscosity modifiers such as sodium chloride, ammonium chloride,
  • the present invention also provides a food composition for preventing or improving hair loss and promoting hair growth or hair growth comprising TYMP protein as an active ingredient.
  • the food composition of the present invention may be in the form of a dietary supplement
  • the "health supplement” refers to a food prepared and processed using raw materials or ingredients having useful functions to the human body according to Act No. 6767 of the Act on Dietary Supplement.
  • “Functional” means ingestion for the purpose of obtaining useful effects on health use such as nutrient control or physiological action on the structure and function of the human body.
  • the food composition may further include food additives, and the suitability as a "food additive", unless otherwise specified, according to the General Regulations of the Food Additives Code and General Test Methods, etc. Judging by the criteria.
  • Items listed in the "Food Additives Code” include, for example, chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, cinnamon acid, natural additives such as navy, licorice extract, crystalline cellulose, guar gum, L- Mixed preparations, such as a glutamate sodium preparation, a noodles addition alkali preparation, a preservative preparation, and a tar pigment preparation, are mentioned.
  • chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, cinnamon acid, natural additives such as navy, licorice extract, crystalline cellulose, guar gum, L- Mixed preparations, such as a glutamate sodium preparation, a noodles addition alkali preparation, a preservative preparation, and a tar pigment preparation, are mentioned.
  • Foods containing the active ingredient of the present invention includes breads, rice cakes, dried fruits, candy, chocolates, chewing gum, confectionery such as ice cream, ice cream products such as ice cream, ice cream powder milk, low fat milk, lactose milk, Processed Milk, Goat Milk, Fermented Milk, Butter Oil, Concentrated Milk, Milk Cream, Butter Oil, Natural Cheese, Processed Cheese, Powdered Milk, Dairy Products such as Whey, Meat Products, Processed Products, Meat Products such as Hamburgers, Ham, Fish products such as sausages, bacon and other processed meat products Ramen noodles, dried noodles, raw noodles, noodle soups, delicacies, dried noodles, improved noodles, frozen noodles, pasta noodles, fruit drinks, vegetable drinks, carbonated drinks, soy milk products, Lactic acid bacteria beverages such as yogurt, beverages such as mixed drinks, soy sauce, miso, red pepper paste, chunjang, cheongukjang, mixed soy sauce, vinegar, sauces, seasoned foods such as tomato ketchup, curry
  • the composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, And carbonating agents used in the carbonated beverage.
  • the composition of the present invention may include a pulp for the production of natural fruit juice, fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not critical but is usually selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
  • the beverage composition including the active ingredient of the present invention is not particularly limited to other ingredients other than the above-mentioned protein, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
  • natural carbohydrates include monosaccharides (eg, glucose, fructose, and the like); Disaccharides (eg maltose, sucrose and the like); And conventional sugars such as polysaccharides (eg dextrin, cyclodextrin, etc.), and sugar alcohols such as xylitol, sorbitol, erythritol.
  • natural flavoring agents tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. have.
  • the present invention also provides a method for preventing or treating hair loss, comprising the step of treating the subject with TYMP protein.
  • the present invention provides a method for improving hair loss comprising the step of treating the subject with a TYMP protein.
  • the present invention provides a method for promoting hair growth or hair growth comprising a; treating the subject with a TYMP protein.
  • TYMPine (thymidine phosphorylase) protein was purchased from Peprotech. The results of analyzing and confirming the amino acid sequence and the DNA base sequence of the obtained TYMP protein are shown in SEQ ID NOs: 1 and 2.
  • DPC Human dermal papilla cell proliferation experiments, a representative in vitro cell test system for measuring hair proliferation, were performed. 1 ng / ml or 5 ng / ml of the TYMP protein of Example 1 was treated with DPC, and the result of measuring proliferation for 40 hours is shown in FIG. 1.
  • the TYMP protein has an excellent cell proliferation effect and thus can be used for hair loss treatment or promotion of hair growth.
  • the measured hair growth weight was found to be 90 mg in the TYMP protein treated group, compared to 40 mg in the control group, and it was confirmed that the hair growth promoting effect was excellent when the TYMP protein was treated. .
  • the TYMP protein component has an excellent hair growth effect and can be used as a composition for preventing and treating hair loss.
  • the above ingredients are mixed and filled in an airtight cloth to prepare a powder.
  • tablets are prepared by tableting according to a conventional method for preparing tablets.
  • the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
  • the amount of the above ingredient is prepared per ampoule (2 ml).
  • Carboxy vinyl polymer 1.5 wt%
  • Carboxy vinyl polymer 1.0 wt%
  • Vitamin B6 0.5 mg
  • composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method.
  • the granules may be prepared and used for preparing a health food composition according to a conventional method.
  • composition ratio is mixed with a component suitable for a favorite beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition comprenant comme principe actif la protéine TYMP, visant à prévenir, traiter ou soulager la chute des cheveux, et à favoriser la pousse des cheveux et le développement des cheveux. La composition de la présente invention, comprenant comme principe actif la protéine TYMP et visant à la prévention de la perte des cheveux et la promotion de la pousse des cheveux, présente un effet remarquable sur la pousse des cheveux, rapidement et sans effets indésirables, lors de son utilisation dans le traitement de la perte de cheveux et peut donc être efficacement utilisée en tant que médicament, ainsi que dans des quasi-médicaments, des produits cosmétiques et des aliments fonctionnels de santé.
PCT/KR2017/008117 2016-08-08 2017-07-27 Composition pharmaceutique comprenant comme principe actif la protéine thymidine phosphorylase (tymp), destinée à la prévention ou au traitement de la chute des cheveux WO2018030683A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0100969 2016-08-08
KR1020160100969A KR101671361B1 (ko) 2016-08-08 2016-08-08 TYMP(thymidine phosphorylase) 단백질을 유효성분으로 포함하는 탈모 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
WO2018030683A1 true WO2018030683A1 (fr) 2018-02-15

Family

ID=57484693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/008117 WO2018030683A1 (fr) 2016-08-08 2017-07-27 Composition pharmaceutique comprenant comme principe actif la protéine thymidine phosphorylase (tymp), destinée à la prévention ou au traitement de la chute des cheveux

Country Status (2)

Country Link
KR (1) KR101671361B1 (fr)
WO (1) WO2018030683A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101671361B1 (ko) * 2016-08-08 2016-11-01 에스씨엠생명과학 주식회사 TYMP(thymidine phosphorylase) 단백질을 유효성분으로 포함하는 탈모 예방 또는 치료용 약학적 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008273A1 (fr) * 1991-10-15 1993-04-29 Delta Biotechnology Limited Phosphorylase de thymidine s'utilisant dans la modulation de la proliferation cellulaire ou de la chimiotaxie
JP2003513619A (ja) * 1999-10-12 2003-04-15 シュヴァルツマン，フリッツ 自己免疫疾患および免疫病因を含む疾患を治療するための遺伝子導入ベクター
KR20140146062A (ko) * 2012-02-07 2014-12-24 글로벌 바이오 테라퓨틱스 유에스에이, 인크. 핵산 전달의 구획화된 방법 및 이의 조성물 및 용도
KR20160005781A (ko) * 2013-05-10 2016-01-15 애리델 에스.피.에이. 하나 이상의 약제학적 관심 물질이 로딩된 적혈구를 제조하는 방법 및 이렇게 하여 수득된 적혈구
KR101671361B1 (ko) * 2016-08-08 2016-11-01 에스씨엠생명과학 주식회사 TYMP(thymidine phosphorylase) 단백질을 유효성분으로 포함하는 탈모 예방 또는 치료용 약학적 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008273A1 (fr) * 1991-10-15 1993-04-29 Delta Biotechnology Limited Phosphorylase de thymidine s'utilisant dans la modulation de la proliferation cellulaire ou de la chimiotaxie
JP2003513619A (ja) * 1999-10-12 2003-04-15 シュヴァルツマン，フリッツ 自己免疫疾患および免疫病因を含む疾患を治療するための遺伝子導入ベクター
KR20140146062A (ko) * 2012-02-07 2014-12-24 글로벌 바이오 테라퓨틱스 유에스에이, 인크. 핵산 전달의 구획화된 방법 및 이의 조성물 및 용도
KR20160005781A (ko) * 2013-05-10 2016-01-15 애리델 에스.피.에이. 하나 이상의 약제학적 관심 물질이 로딩된 적혈구를 제조하는 방법 및 이렇게 하여 수득된 적혈구
KR101671361B1 (ko) * 2016-08-08 2016-11-01 에스씨엠생명과학 주식회사 TYMP(thymidine phosphorylase) 단백질을 유효성분으로 포함하는 탈모 예방 또는 치료용 약학적 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PUGLISI, F.: "Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer", ANNALS OF ONCOLOGY, vol. 19, no. 9, September 2008 (2008-09-01), pages 1541 - 1546, XP055603508, ISSN: 0923-7534, DOI: 10.1093/annonc/mdn165 *

Also Published As

Publication number Publication date
KR101671361B1 (ko) 2016-11-01

Similar Documents

Publication Publication Date Title
WO2018030590A1 (fr) Composition destinée à prévenir ou à traiter la perte de cheveux comprenant une protéine de ligand 1 de chimiokine (motif c-x-c) (cxcl1) à titre de principe actif
WO2021149880A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser la croissance capillaire, comprenant, en tant que principe actif, un extrait mixte de concombre, d'aubergine et d'escargot
WO2020204275A1 (fr) Composition pour la prévention de la chute des cheveux ou la stimulation de la pousse des cheveux
WO2020218720A1 (fr) Composition pour la prévention ou le traitement de troubles musculaires ou l'amélioration de la fonction musculaire, contenant un extrait de leonurus japonicus ou de la léonurine
WO2010123184A1 (fr) Composition pour prévenir et traiter l'alopécie, à base de composés de norgalanthamine
WO2018117725A1 (fr) Composition pour prévenir la chute des cheveux et favoriser la pousse des cheveux, comprenant des produits animaux marins fermentés
WO2024010255A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de la chute des cheveux, contenant un extrait de connarus semidecandrus jack.
WO2021080388A1 (fr) Composition pour prévenir ou traiter l'infection par le virus de la diarrhée épidémique porcine, comprenant un complexe contenant un composé à base de curcuminoïde et un extrait de réglisse ou une fraction de celui-ci
WO2018030683A1 (fr) Composition pharmaceutique comprenant comme principe actif la protéine thymidine phosphorylase (tymp), destinée à la prévention ou au traitement de la chute des cheveux
US10512670B2 (en) Pharmaceutical composition for preventing or treating hair loss comprising chemokine (C-X-C motif) ligand 1 (CXCL1) protein or CXCL1 protein and minoxidil as active ingredient
WO2018080039A1 (fr) Composition destinée à prévenir la chute des cheveux ou à améliorer la croissance des cheveux, contenant un extrait de feuilles de soja de couleur jaune
WO2019168348A1 (fr) Composition de prévention de la chute des cheveux et de stimulation de la pousse des cheveux
WO2021251790A1 (fr) Conjugué acide désoxycholique-peptide à activité anti-obésité et son utilisation
WO2017142368A2 (fr) Composition permettant de prévenir et de traiter une maladie cutanée allergique ou inflammatoire
KR102000217B1 (ko) Cxcl1 단백질 및 미녹시딜을 유효성분으로 포함하는 탈모 예방 또는 치료용 약학적 조성물
WO2021107381A1 (fr) Composition comprenant de l'acide férulique et des analogues de celui-ci pour prévenir et traiter des maladies cutanées causées par une mutation génétique
WO2021002642A1 (fr) Composition pour prévenir ou traiter la polyarthrite rhumatoïde, comprenant du venin de serpent
WO2014185610A1 (fr) Composition pour prévenir la perte de cheveux ou favoriser la pousse des cheveux du fait de son contenu en extrait de son comme principe actif
WO2021125733A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de la perte de cheveux
WO2018139885A1 (fr) Composition contenant de l'acétate d'acétoxychavicol en tant que principe actif pour prévenir la chute des cheveux ou activer la pousse des cheveux
WO2022231294A1 (fr) Composition destinée à prévenir, à atténuer ou à traiter la pigmentation de la peau
WO2020218840A1 (fr) Composition pour inhiber la perte des cheveux ou favoriser la pousse des cheveux contenant un extrait de plante débarrassé de chlorophylle ou de pigment en tant que principe actif, et son procédé de production
WO2024136513A1 (fr) Composition pour favoriser la pousse des cheveux, contenant du mucus d'esturgeon utilisé en tant que principe actif
WO2024080400A1 (fr) Peptide ayant une activité favorisant la pousse des cheveux et supprimant la chute des cheveux et son utilisation
WO2020235759A1 (fr) Composition pour favoriser la pousse des cheveux et atténuer et traiter la chute des cheveux et comprenant la substance p

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17839701

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17839701

Country of ref document: EP

Kind code of ref document: A1